

Adenosine

| CAUTION: High Administration Risk Rating | |
|--|---|
| Form | 6mg per 2mL vial |
| Reconstitution | Already in solution |
| Compatibility and Stability | N/A |
| Administration | <p><u>IV Injection only</u> Rapid IV bolus over 2 seconds either directly into central or large peripheral vein or into an IV line. If given into an IV line, it should be injected as close to the cannulation site as possible. Follow by a rapid sodium chloride 0.9% flush.</p> |
| Monitoring & Adverse Drug Reactions | <ul style="list-style-type: none"> • Adenosine should only be used where facilities for cardiac monitoring and cardiorespiratory resuscitation equipment exist. • The occurrence of angina, severe bradycardia, severe hypotension, respiratory failure, or asystole/cardiac arrest, should lead to immediate discontinuation of administration. • Side effects are generally short lived as half-life is less than 10 seconds. They include facial flushing, shortness of breath, nausea, heart block, dizziness, headache and hypotension. |

Information provided relates to Adenocor® manufactured by Sanofi-Aventis.